B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., Chang, J. E., Chavez, J. C., Christian, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Harris, N., Hernandez-Ilizaliturri, F., Kaminski, M. S., Kelsey, C. R., Khan, N., Krivacic, S., LaCasce, A. S., Mehta, A., Nademanee, A., Rabinovitch, R., Reddy, N., Reid, E., Roberts, K. B., Smith, S. D., Snyder, E. D., Swinnen, L. J., Vose, J. M., Dwyer, M. A., Sundar, H. 2019; 17 (6): 651–61

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

View details for DOI 10.6004/jnccn.2019.0029

View details for Web of Science ID 000473277200004

View details for PubMedID 31200358